INFLUÊNCIA DO USO DO FITOCANABINOIDE CANABIDIOL EM DOENÇAS NEURODEGENERATIVAS

• DOI: https://doi.org/10.22533/at.ed.8208142511093

• Palavras-chave: Canabinóides; Doenças Neurodegenerativas; Fitocanabinoides; Canabidiol.

• Keywords: -

• Abstract: Neurodegenerative diseases impair motor and cognitive functions, as well as the patient's homeostasis, directly impacting quality of life. Current treatments focus primarily on symptomatic relief, with progressively decreasing efficacy as degeneration advances, since these disorders are characterized by the gradual loss of nerve cells in the central and/or peripheral nervous system. In this context, the use of phytocannabinoids, particularly cannabidiol (CBD), has emerged as a promising adjuvant therapy for conditions such as Alzheimer’s and Parkinson’s disease. Unlike tetrahydrocannabinol (THC), CBD does not produce significant psychoactive effects, making it a safe alternative for clinical use. Various preclinical and clinical studies suggest that CBD exerts neuroprotective, antioxidant, anti-inflammatory, and neurotransmission-modulating effects, potentially benefiting disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). Despite these promising findings, large-scale randomized clinical trials are still required to confirm the efficacy, safety, optimal dosage, and molecular mechanisms of CBD in each specific condition. Advances in this field may offer a novel adjunctive therapeutic approach in the management of neurodegenerative diseases, which are often resistant to traditional treatments. The present study aims to observe and clarify the effects of CBD when applied as a therapeutic option in the management of neurodegenerative disorders.